In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp.
Scedosporium spp. are significant fungal pathogens in both immunocompromised and immunocompetent individuals. The effectiveness of antifungal therapy against Scedosporium spp. is limited due to their multidrug resistance to most widely used antifungal chemotherapies such as azoles, polyenes and echinocandins (Tortorano et al., 2014) . Voriconazole, sometimes combined with surgery, appears to be the only drug significantly active against scedosporiosis. However, the mortality due to scedosporiosis remains high and finding more effective antifungal strategies is necessary. Antifungal combination treatment of drugs belonging to different classes may be a useful approach. So far, azoles in combination with echinocandins or polyenes or terbinafine, as well as polyenes in combination with other drugs, have been tested in vitro with various results (Afeltra et al., 2002; CuencaEstrella et al., 2008; Lackner et al., 2014; Meletiadis et al., 2003; Rodríguez et al., 2009; Troke et al., 2008; Yustes & Guarro, 2005) .
Miltefosine, an alkyl phosphocholine compound first developed as an anticancer agent and known to be active against Leishmania spp. and Trypanosoma cruzi, has also shown broad-spectrum antifungal activity in vitro (Tong et al., 2007; Widmer et al., 2006) including against Scedosporium spp. In vitro data on miltefosine combination therapy remain scarce and results are contradictory (Biswas et al., 2013; Imbert et al., 2014) . Moreover, no clinical studies guiding the use of this new compound have been published, and only three cases illustrating the use of miltefosine alone (Ferguson et al., 2013) or in combination with voriconazole and terbinafine (Kesson et al., 2009; Trubiano et al., 2014) have been reported. The aim of this study was to evaluate the in vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp.
Eleven clinical isolates of Scedosporium spp. from two university hospitals (Hôpital Henri Mondor and Hô pital Européen Georges Pompidou, Paris, France) were tested in this study. Isolates were identified to species level using molecular and/or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry as described previously (Sitterlé et al., 2013) . The MICs of miltefosine, amphotericin B and voriconazole alone and in combination were evaluated using a two-dimensional broth chequerboard method according to Clinical and Laboratory Standards Institute standard M38-A2 as described by Dannaoui et al. (2004) . The end point was defined as 100 % inhibition of growth for all three drugs alone and in combination compared with the control after 72 h of incubation at 35 u C. Based on preliminary results, the concentration range of both amphotericin B and voriconazole (0. 
